tldrdaily.news logo
Tag

Crb 701

All articles tagged with #crb 701

healthcare1 year ago

"Corbus Pharmaceuticals' Stock Soars 300% on Positive Phase 1 Cancer Study Results"

Corbus Pharmaceuticals' shares surged over 200% after reporting positive results from its Phase 1 study of CRB-701, a next generation nectin-4 targeting antibody drug conjugate, showing encouraging safety and efficacy in patients with nectin-4 positive tumors. The study is being conducted in China and enrolling participants with metastatic urothelial cancer and other solid tumors confirmed to have nectin-4 positive tumors.

via MarketWatch|
#cancer-study#corbus-pharmaceuticals#crb-701
healthcare2 years ago

"CRB-701: Promising Results in First-in-Human Study for Nectin-4 Positive Tumors"

Corbus Pharmaceuticals presented encouraging safety and efficacy data for CRB-701 (SYS6002), a next-generation antibody drug conjugate targeting nectin-4 positive tumors, at the 2024 ASCO GU Symposium. The Phase 1 study in China showed a 43% overall response rate and 71% disease control rate at predicted therapeutically relevant doses, with no dose-limiting toxicities observed up to 3.6 mg/kg. The drug demonstrated a differentiated pharmacokinetic profile and a safety profile devoid of peripheral neuropathy and skin rash, suggesting potential benefits for metastatic urothelial cancer and other nectin-4 positive solid tumors. Dose escalation and expansion are ongoing, with plans to commence a clinical study in the US in Q1 2024.

via GlobeNewswire|
#antibody-drug-conjugate#cancer-treatment#crb-701
healthcare2 years ago

"Promising Results for CRB-701 (SYS6002) in First-In-Human Study at ASCO-GU 2024"

Corbus Pharmaceuticals presented encouraging safety and efficacy data for CRB-701 (SYS6002), a next-generation antibody drug conjugate targeting nectin-4 positive tumors, at the 2024 ASCO GU Symposium. The Phase 1 study in China showed a 43% overall response rate and 71% disease control rate at predicted therapeutically relevant doses, with no dose-limiting toxicities observed up to 3.6 mg/kg. The drug demonstrated a differentiated pharmacokinetic profile and a safety profile devoid of peripheral neuropathy and skin rash, prompting plans for further investigation and expansion of the study.

via GlobeNewswire|
#antibody-drug-conjugate#cancer-treatment#crb-701